Silo Pharma, Inc.

Announcement of Cryptocurrency Treasury Strategy and Formation of Crypto Advisory Board.

On August 4, 2025, our Board of Directors (“Board”) approved the establishment of a cryptocurrency advisory board (the “Crypto Advisory Board”) which will initially consist of up to three (3) members in connection with our Company’s cryptocurrency treasury strategy focused on leading digital assets, including Bitcoin, Ethereum, and Solana. On August 4, 2025. the Board appointed Corwin Yu as the initial member of the Crypto Advisory Board.

On August 5, 2025, we announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets.

Update on Previously Announced Potential Joint Venture with Hoth Therapeutics, Inc.

On June 25, 2025, we announced that we had entered into a non-binding letter of intent to form a strategic joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University. The parties to the letter of intent have mutually decided not to move forward with the joint venture.

Material changes to the procedures by which security holders may recommend nominees to the board of directors.

None.

Director and Officer Trading Arrangements

During our quarter ended September 30, 2025, none of our directors or executive officers adopted, modified orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as such terms are defined under Item 408 of Regulation S-K of the Exchange Act.